Newsroom

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een mondiaal oncologisch bedrijf, herbevestigt zijn positie als leider in innovaties voor chronische lymfatische leukemie (CLL) door de breedte, kwaliteit en het momentum van zijn hematologisch portfolio te demonstreren op de 67ste jaarlijkse vergadering en expositie van ASH in Orlando, Florida. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp...

TORONTO--(BUSINESS WIRE)--Almonty Industries Inc. (“Almonty” or the “Company“) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated October 31, 2025 (the “Base Prospectus”), in connection with a proposed public offering of 15 million of Almonty’s common shares (“Common Shares”) in the United States (the “Offering”...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda farmaceutica oncologica globale, riafferma la sua posizione come leader innovativo nella leucemia linfatica cronica (LLC) mostrando la profondità, la qualità e lo slancio del suo portafoglio ematologico al 67o Meeting annuale ed Esposizione dell'American Society of Hematology (ASH) a Orlando, Florida. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale d'oncologie, annonce aujourd'hui de nouvelles données sur le sonrotoclax, un inhibiteur de BCL2 expérimental de nouvelle génération, démontrant un bénéfice clinique significatif en monothérapie et en combinaison contre des tumeurs malignes à cellules B. Ces données ont été présentées lors de la 67e réunion annuelle de l'American Society of Hematology (ASH) à Orlando,...

NEW YORK--(BUSINESS WIRE)--Last November, the Ministry of Tourism of the Dominican Republic marked a milestone year for the country’s tourism by hosting more than 800 guests—including travel agents, tour operators, airline and cruise line executives, and travel industry leaders—at the iconic Cipriani Wall Street. The event followed the announcement of remarkable tourism results, with 3,730,852 nonresident air travelers from the United States visiting the Dominican Republic between January and O...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（Nasdaq: ONC、HKEX: 06160、SSE: 688235）は、次世代の治験中BCL2阻害薬であるソンロトクラックスについて、B細胞悪性腫瘍全体にわたり単剤療法および併用療法のいずれにおいても臨床的に意義のある有益性を示した新たなデータを発表しました。これらのデータは、フロリダ州オーランドで開催された第67回米国血液学会（ASH）年次総会・展示会で発表されました。今回の5件の発表では、前治療歴の多い再発／難治性（R/R）マントル細胞リンパ腫（MCL）患者における持続的な奏効に加え、未治療の慢性リンパ性白血病（CLL）患者においてソンロトクラックスをベースとする併用療法により、深く迅速かつ持続的な検出不能微小残存病変（uMRD）の達成率が示されており、本剤がB細胞悪性腫瘍における基盤的治療薬となる可能性を浮き彫りにしています。 「今回、ASH 2025で発表しているデータは、次世代BCL2阻害薬としてのソンロ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida. SonoThera’s oral presentation focuses on the safe delivery of DNA expression vectors to the liver in non-human primate (NHP) models using...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy nuevos datos sobre Sonrotoclax, un inhibidor de BCL2 de próxima generación en investigación, que muestran beneficios clínicos significativos tanto en monoterapia como en combinaciones para diversas neoplasias de células B. Estos resultados se presentaron en la 67ª Reunión y Exposición Anual de la Sociedad Estadounidense de Hematología (ASH, American Soc...

CINCINNATI--(BUSINESS WIRE)--Today, Fifth Third Bancorp announced the declaration of cash dividends on its common shares, Series H preferred shares, Series I preferred shares, Series J preferred shares, Series K preferred shares, and Class B Series A preferred shares. Fifth Third Bancorp (Nasdaq: FITB) today declared a cash dividend on its common shares of $0.40 per share for the fourth quarter of 2025. The dividend is payable on January 15, 2026 to shareholders of record as of December 31, 202...